- Austria / Österreich
- Bosnia and Herzegovina / Босна и Херцеговина
- Bulgaria / България
- Croatia / Hrvatska
- Czech Republic & Slovakia / Česká republika & Slovensko
- France / France
- Germany / Deutschland
- Greece / ΕΛΛΑΔΑ
- Italy / Italia
- Netherlands / Nederland
- Nordic / Nordic
- Poland / Polska
- Portugal / Portugal
- Romania & Moldova / România & Moldova
- Slovenia / Slovenija
- Serbia & Montenegro / Србија и Црна Гора
- Spain / España
- Switzerland / Schweiz
- Turkey / Türkiye
- UK & Ireland / UK & Ireland
A medicine that was being developed for cancer has shown potential in modulating the immune response to prevent the deadly cytokine storm. Researchers call it a breakthrough as 29 of 30 phase 1 trial patients left hospital within 3-5 days.
Tel Aviv’s Ichilov Medical Center has successfully completed the phase 1 trials for a new drug that appears to have helped numerous moderate-to-serious cases to quickly recover from COVID-19. The hospital calls it a huge breakthrough as all 30 patients suffering from moderate to severe Covid-19, who received the drug recovered — 29 of them within three to five days.
EXO-CD24 -a targeted drug that was being developed as a cure for cancer for the past few years, makes use of tiny carrier sacs knows as exosomes to deliver a protein called CD24 to the lungs. The drug fights the cytokine storm, which is an overreaction to the SARS-CoV-2 infection by the immune system that is believed to be potentially lethal.
The drug EXO-CD24 is different from other molecules in that it is directly inhaled into the lungs, which happen to be the epicentres of the cytokine storm. It is to be inhaled once a day for a few minutes, for five days.
Tags:
Fri. 26 April 2024
9:30 pm IST (New Delhi)
How you can access data-driven decision making
Mon. 29 April 2024
10:00 pm IST (New Delhi)
Root caries: The challenge in today’s cariology
Tue. 30 April 2024
10:30 pm IST (New Delhi)
Neodent Discovery: Neoarch Guided Surgery—from simple to complex cases
Fri. 3 May 2024
10:30 pm IST (New Delhi)
Osseointegration in extrēmus: Complex maxillofacial reconstruction & rehabilitation praeteritum, praesens et futurum
Wed. 8 May 2024
5:30 am IST (New Delhi)
You got this! Diagnosis and management of common oral lesions
Fri. 10 May 2024
5:30 am IST (New Delhi)
Empowering your restorative practice: A comprehensive guide to clear aligner integration and success
Mon. 13 May 2024
10:30 pm IST (New Delhi)
To post a reply please login or register